AAOS 2016: TXA reduces total blood loss in extra-capsular hip fractures .
Tranexamic Acid (TXA) Reduces Blood Loss in Patients with Hip Fractures; Results of a Randomized Controlled Trial
72 patients undergoing extra-capsular hip fracture surgery were randomized to administered either tranexamic acid (TXA) or placebo. The purpose of this study was to determine the efficacy of TXA for reducing total blood loss compared to a saline control group. Secondary outcomes included transfusion rate and 90-day mortality rate. Findings indicated significantly lower blood loss in the TXA group compared to the placebo group. Number of transfusions and 90-day mortality did not significantly differ between groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
